Field Safety Notices: 9 - 13 March 2026
UKField Safety Notices: 9 - 13 March 2026
Recalling Firm: MHRA
Reason for Recall / Hazard
A list of Field Safety Notice for 9 - 13 March 2026...
Product Description & Identification
A list of Field Safety Notice for 9 - 13 March 2026
Affected Products
Field Safety Notices: 9 - 13 March 2026
Additional Source Details
| Field | Value |
|---|---|
| Guid | tag:www.gov.uk,2005:/drug-device-alerts/field-safety-notices-9-13-march-2026 |
| Link | https://www.gov.uk/drug-device-alerts/field-safety-notices-9-13-march-2026 |
| Pub Date | 2026-03-20T14:43:34+00:00 |
| Extracted category | devices |
Check Other Products In Your Household
Free Safety ToolsSafety recalls are issued daily across foods, medications, vehicles, and electronics. Use our instant tools to check your home for active safety warnings:
Overview
- Recalling FirmMHRA
- Risk LevelMedical Device Alert
- DistributionUnited Kingdom
📢 Share Warning
Alert family and friends to keep them safe. Copy this quick alert message:
🚨 SAFETY ALERT: MHRA - Field Safety Notices: 9 - 13 March 2026 Check if your household is affected: https://therecallfile.com/recalls/field-safety-notices-9-13-march-2026/UK-MHRA-field-safety-notices-9-13-march-2026
Join Alertlist
Get instant email updates whenever critical safety recalls like this are published.
Related Recalls
UKField Safety Notices: 13 to 17 July 2026
Field Safety Notices: 13 to 17 July 2026
List of Field Safety Notices from 13 to 17 July 2026....
FDA DevicesAquacel Ag Surgical SP REF: 413556 9cm x 15cm/3.5 in. x 6 in., Sterile R
Aquacel Ag Surgical SP REF: 413556 9cm x 15cm/3.5 in. x 6 in., Sterile R
Surgical dressing manufactured out of specification (greater thickness).
FDA DevicesGSP Neonatal GALT Kit. Product Codes: 3303-001U, 3303-0010. in vitro diagnostic. Used in FLUORESCENT PROC. (QUAL), GALACTOSE-1-PHOSPHATE URIDYL TRANSFERASE.
GSP Neonatal GALT Kit. Product Codes: 3303-001U, 3303-0010. in vitro diagnostic. Used in FLUORESCENT PROC. (QUAL), GALACTOSE-1-PHOSPHATE URIDYL TRANSFERASE.
Reduction in the on-board stability of the GSP GALT assay. This may increase the likelihood of run-QC failures and consequently delay the reporting of patient results.